Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amylx Pharmaceuticals Inc (AMLX) vs Seagate Technology Holdings PLC (STX) Price & Performance

Amylx Pharmaceuticals IncTrade
Seagate Technology Holdings PLCTrade

Price performance (Past 24H)

Key statistics

Amylx Pharmaceuticals Inc vs Seagate Technology Holdings PLC — how do they compare? Amylx Pharmaceuticals Inc trades at $23.91 (market cap $2.64B), while Seagate Technology Holdings PLC trades at $882.62 (market cap $185.97B). The key difference: Seagate Technology Holdings PLC is far larger — about 70.4× Amylx Pharmaceuticals Inc's market cap, and Seagate Technology Holdings PLC pays a 0.36% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

AMLXSTX
Market Cap
$2.64B$185.97B
Sector
HealthTechnology
52-Week High
$24.19$1.09K
52-Week Low
$7.82$154.43
Enterprise Value
$2.39B$188.12B
Dividend Yield
0.36%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amylx Pharmaceuticals Inc

AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.

Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.

Seagate Technology Holdings PLC

Seagate Technology (STX) trades at $800.74, down 1.48% today, with a bearish technical signal but strong recent earnings beats driven by AI storage demand. The company reported Q2 2026 EPS of $5.71, beating expectations of $5.10, with revenue growth and margin expansion supported by its HAMR technology and data center contracts. However, high valuation ratios (P/E 59.03, P/S 15.41) and negative shareholder equity pose fundamental concerns.

The outlook is mixed: AI-driven demand and analyst bullishness (54.91% buy ratings) support upside to the $1,130 consensus target, but elevated valuation, legal settlements, and competitive pressures in the storage market present significant risks. Cash flow volatility and debt levels require monitoring for sustained growth.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amylx Pharmaceuticals Inc

Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.

Read more on AMLX

About Seagate Technology Holdings PLC

Seagate is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital

Read more on STX